TY - JOUR
TI - MABp1 targeting interleukin-1α in hidradenitis suppurativa ineligible for adalimumab treatment: results of the open-label extension period
AU - Kanni, T.
AU - Argyropoulou, M.
AU - Dinarello, C.A.
AU - Simard, J.
AU - Giamarellos-Bourboulis, E.J.
JO - CLINICAL AND EXPERIMENTAL DERMATOLOGY
PY - 2021
VL - 46
TODO - 1
SP - 162-163
PB - Wiley-Blackwell Publishing Ltd
SN - null
TODO - 10.1111/ced.14333
TODO - adalimumab;  bermekimab;  interleukin 1alpha;  placebo;  adalimumab;  IL1A protein, human;  interleukin 1alpha;  MABp1 monoclonal antibody;  monoclonal antibody, clinical article;  controlled study;  disease exacerbation;  double blind procedure;  drug efficacy;  drug targeting;  follow up;  human;  Letter;  open study;  patient-reported outcome;  phase 2 clinical trial;  priority journal;  randomized controlled trial;  suppurative hidradenitis;  chemistry;  drug tolerance;  intravenous drug administration;  metabolism;  organization and management;  phase 2 clinical trial (topic);  randomized controlled trial (topic);  safety;  suppurative hidradenitis;  treatment outcome, Adalimumab;  Antibodies, Monoclonal;  Antibodies, Monoclonal, Humanized;  Clinical Trials, Phase II as Topic;  Drug Tolerance;  Eligibility Determination;  Hidradenitis Suppurativa;  Humans;  Infusions, Intravenous;  Interleukin-1alpha;  Patient Reported Outcome Measures;  Placebos;  Randomized Controlled Trials as Topic;  Safety;  Treatment Outcome
TODO - null
ER -